A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07030699
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Epcoritamab — DRUG
    Subcutaneous, once weekly in cycles 1-3; every 4 weeks cycles 4-12
  • Lenalidomide — DRUG
    Oral, daily on days 1-21 of a 28-day cycle
  • Tafasitamab — DRUG
    Intravenous, once weekly during cycles 1-3, then every 2 weeks during cycle 4-12

Study Details

The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL. This is the first time the combination of drugs is being tested.

Key Dates

Start date
Aug 13, 2025
Status verified
Apr 2026
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Epcoritamab with Lenalidomide and Tafasitamab
    Epcoritamab: Subcutaneous, once weekly in cycles 1-3; every 4 weeks cycles 4-12. Tafasitamab: Intravenous, once weekly during cycles 1-3, then every 2 weeks during cycle 4-12. Lenalidomide: Oral, daily on days 1-21 of a 28-day cycle.

Primary Outcome Measure

best complete response rate (CRR) [ Time Frame: 2 years ]

Related Studies